newsfilter
← Latest News
GlobeNewswire·

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in